Completed PHASE3 NCT00675623

A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease

A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease (CONNECTION)

Sponsor: Medivation, Inc.

Conditions Alzheimer's Disease

Interventions Dimebon Placebo

Updated 8 times since 2017 Last updated: Sep 24, 2016 Started: May 31, 2008 Primary completion: Dec 31, 2009

Listed as NCT00675623, this PHASE3 trial focuses on Alzheimer's Disease and remains completed. Sponsored by Medivation, Inc., it has been updated 8 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medivation, Inc.

Data source: Medivation, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Austin, United States , Brooklyn, United States , Cedarhurst, United States , Centerville, United States , Costa Mesa, United States , Fresno, United States , Hallandale, United States , Hamden, United States , Hialeah, United States and 18 more locations